MARKET

NBY

NBY

Novabay Pharma
AMEX

Real-time Quotes | Nasdaq Last Sale

0.1925
+0.0015
+0.79%
After Hours: 0.1930 +0.0005 +0.26% 19:33 05/27 EDT
OPEN
0.1990
PREV CLOSE
0.1910
HIGH
0.2047
LOW
0.1802
VOLUME
496.37K
TURNOVER
0
52 WEEK HIGH
0.8772
52 WEEK LOW
0.1711
MARKET CAP
10.13M
P/E (TTM)
-1.6509
1D
5D
1M
3M
1Y
5Y
NovaBay Pharmaceuticals: Q1 Earnings Insights
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/12 21:12
NovaBay GAAP EPS of $0.00 beats by $0.03, revenue of $2.63M misses by $0.63M
NovaBay press release (NYSE:NBY): Q1 GAAP EPS of $0.00 beats by $0.03. Revenue of $2.63M (+45.3% Y/Y) misses by $0.63M.
Seekingalpha · 05/12 20:17
NovaBay Pharmaceuticals Q1 EPS $0.00 Beats $(0.03) Est., Sales $2.60M Miss $3.26M Estimate
NovaBay Pharmaceuticals (AMEX:NBY) reported quarterly sales of $2.60 million which missed the analyst consensus estimate of $3.26 million by 20.25 percent. This is a 43.88 percent increase over sales of $1.81 million
Benzinga · 05/12 20:10
-- Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.6M, vs. Street Est of $3.26M
MT Newswires · 05/12 16:28
NovaBay Q1 2022 Earnings Preview
NovaBay (NBY) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $3.26M (+80.1%
Seekingalpha · 05/11 21:35
Earnings Outlook For NovaBay Pharmaceuticals
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that NovaBay Pharmaceuticals will report an earnings per share (EP...
Benzinga · 05/11 17:04
NovaBay introduces new skincare products with anti-aging formulations
NovaBay Pharmaceuticals (NYSE:NBY) said it expanded its top-selling Kakadu C and Calm Cool + Corrected product lines by introducing new products with anti-aging ingredients to help reduce the appearance of
Seekingalpha · 05/09 11:29
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C And Calm Cool + Corrected Collections With New Anti-Aging Formulations
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the expansion of its top-selling
Benzinga · 05/09 10:54
More
No Data
Learn about the latest financial forecast of NBY. Analyze the recent business situations of Novabay Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NBY stock price target is 3.100 with a high estimate of 4.000 and a low estimate of 2.200.
High4.000
Average3.100
Low2.200
Current 0.1925
EPS
Actual
Estimate
-0.04-0.03-0.02-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 20
Institutional Holdings: 647.60K
% Owned: 1.23%
Shares Outstanding: 52.62M
TypeInstitutionsShares
Increased
3
383.59K
New
7
174.48K
Decreased
6
97.70K
Sold Out
2
12.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Paul Freiman
Chief Executive Officer/Chief Compliance Officer/General Counsel/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Other/Director
Audrey Kunin
Director
Mijia Wu
Director
Yongxiang Zheng
Independent Director
Julie Garlikov
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
No Data
No Data
About NBY
NovaBay Pharmaceuticals, Inc. is a medical device company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is a solution of hypochlorous acid that acts as an antimicrobial preservative in solution and has been shown to neutralize bacterial toxins in laboratory tests. It develops additional products containing its hypochlorous acid, including NeutroPhase and PhaseOne for the wound care market. The Company's dermatology product includes CelleRx Clinical Reset, which is a facial spray that disrupts the layer of bacteria that settles and grows on the face. Its wound care business includes the business of NeutroPhase and PhaseOne product, which are used for the cleansing and irrigation of intraoperative pocket lavage, stasis ulcers, leg ulcers, diabetic foot ulcers, minor burns, superficial abrasions, wounds and moistening absorbent wound dressings.

Webull offers kinds of NovaBay Pharmaceuticals, Inc. stock information, including AMEX:NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.